|
Best Practices, LLC Research Highlights Critical Role of Medical Affairs in New Product Launch Success
CHAPEL HILL, N.C. – January 14, 2011. New Product Planning (NPP) groups play a vital role in many of the new product development activities that set the stage for a successful launch. One of the areas of growing importance for NPP groups is medical affairs activities such as ad boards, and thought leader identification and education.
The Best Practices, LLC benchmarking report New Product Planning: Role and Activities for Medical Affairs provides a detailed examination of the timing and value of Medical Affairs activities.
Key chapters in this 50-slide report are:
- The current state of New Product Planning in pharma
The central challenge is to ensure that the right new products get developed efficiently—with minimum risk and maximum value—to allow senior management to make smart decisions confidently.
- Overview of New Product Planning activities and timing during development process
Reviews Key Patterns and Activities that drive the New Product Planning process
Pre-clinical through Phase II: NPP engages in a series of activities from Pre-Clinical through Phase 2 designed to determine the market fit and potential of identified candidates and to prepare for key activities, such as positioning and branding.
Phase III through Commercial Handoff: After Phase II, NPP activities are more focused as more clinical data becomes available and outputs are refined to support critical commercial activities and maximize the product’s launch and lifecycle success.
This chapter also reviews the main Medical Affairs activities carried out during the development process - analysis provides drill down for each of these activities in terms of their timing, intended outcomes, and value for the organization
- Advisory Boards
- Branding of the Science
- KOL Identification
- KOL Management
- Medical Meeting Planning
- Non-Registration Trials Strategy and Planning
- Publication Strategy & Planning
To download a complimentary study excerpt, go to: http://www.best-in-class.com/rr1038.htm
Best Practices, LLC used both field surveys and interviews to complete this study. In all, 27 New Product Planning leaders at 25 pharma companies across the globe contributed data. In-depth interviews were conducted with leaders from 13 of the participating companies.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC’s clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.
|
|